Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CVT/Astellas To Submit Regadenoson In Mid-2007, Following Successful Phase III Studies

This article was originally published in The Pink Sheet Daily

Executive Summary

Selective adenosine receptor agonist could replace market leader Adenoscan as the myocardial perfusion imaging agent of choice, CVT says.

You may also be interested in...



FDA Clears Astellas’ Lexiscan For Market

Bigger sales force backs soon-to-launch imaging agent.

FDA Clears Astellas’ Lexiscan For Market

Bigger sales force backs soon-to-launch imaging agent.

CVT/Astellas Submit Next-Gen Cardiac Stress Agent Regadenoson

CV Therapeutics and Astellas Pharma submitted an NDA for their novel cardiac imaging stress agent regadenoson May 14, CVT told "The Pink Sheet" DAILY

Related Content

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel